P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Saad Z. Usmani,Hareth Nahi,Torben Plesner,Brendan M. Weiss,Nizar J. Bahlis,Andrew Belch,Peter M. Voorhees,Jacob P. Laubach,Niels W.C.J. van de Donk,Tahamtan Ahmadi,Clarissa M. Uhlar,Jianping Wang,Huaibao Feng,Ming Qi,Paul G. Richardson,Sagar Lonial +15 more
TL;DR: In this analysis, daratumumab 16 mg/kg monotherapy showed durable responses and there were no new safety concerns with longer follow-up of these two studies.
Journal ArticleDOI
Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma
Maria-Victoria Mateos,María Teresa Cibeira,Paul G. Richardson,Felipe Prosper,Albert Oriol,Javier de la Rubia,Juan José Lahuerta,Ramón García-Sanz,Sonia Extremera,Sergio Szyldergemajn,Claudia Corrado,Harald Singer,Constantine S. Mitsiades,Kenneth C. Anderson,Joan Bladé,Jesús F. San Miguel +15 more
TL;DR: Single-agent plitidepsin has limited but reproducible activity in relapsed/refractory multiple myeloma patients and activity observed after dexamethasone addition merits further study.
Journal ArticleDOI
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study
Stephanie J. Lee,Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Jesús F. San Miguel,Bruce Crawford,Joseph M. Massaro,Ravinder Dhawan,Sanjay Gupta,Kenneth C. Anderson +10 more
TL;DR: Health‐related quality of life (HRQL) was prospectively measured during the phase III APEX trial of bortezomib versus dexamethasone in relapsed multiple myeloma patients and shows that bortzomib was associated with significantly better multidimensional HRQL compared with dexamETHasone, consistent with the better clinical outcomes seen with bortazomib.
Journal ArticleDOI
Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis
Ewan Forrest,Stephen R. Atkinson,Paul G. Richardson,Steven Masson,Stephen D. Ryder,Mark Thursz,Michael Allison,Anne McCune,Dermot Gleeson,Andrew Austin,David Patch,Ashwin Dhanda,Debbie L. Shawcross,Mark Wright +13 more
TL;DR: The three newer static scores (ABIC, ABIC and MELD) were shown to be superior to the oldest score (DF) and could also identify patients who had a survival benefit 28 days after starting prednisolone treatment.
Journal ArticleDOI
KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
Hiroto Ohguchi,Takeshi Harada,Morihiko Sagawa,Shohei Kikuchi,YT Tai,Paul G. Richardson,Teru Hideshima,Kenneth C. Anderson +7 more
TL;DR: It is shown that KDM6B is expressed in multiple myeloma (MM) cells; and that shRNA-mediated knockdown and CRISPR-mediated knockout of KDM 6B abrogate MM cell growth and survival.